SCHEMBL6569253

SCHEMBL6569253

Cc1cccc(C(=O)N/N=C\c2cc(Cl)ccc2O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 1/20 0.69
KDM1A O60341 4/20 0.67
MEN1 O00255 7/20 0.66
KMT2A Q03164 7/20 0.66
RAB9A P51151 5/20 0.66
NPC1 O15118 5/20 0.66
KLF5 Q13887 1/20 0.66
KDM4E B2RXH2 4/20 0.65
HTT P42858 3/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
LMNA P02545 2/20 0.65
POLB P06746 2/20 0.65
PSMD14 O00487 1/20 0.65
MMP2 P08253 1/20 0.65
BLM P54132 1/20 0.65
MITF O75030 1/20 0.65
GPR174 Q9BXC1 1/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
MAPT P10636 3/20 0.59
CYP1A2 P05177 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6569257 1.00 PIK3CG (0.69) PIK3CGKDM1AMEN1KMT2ARAB9A
SCHEMBL684997 1.00 PIK3CG (0.69) PIK3CGKDM1AMEN1KMT2ARAB9A
SCHEMBL684769 0.90 KDM1A (0.66) PIK3CGKDM1AMEN1KMT2ARAB9A
SCHEMBL684661 0.90 KDM1A (0.73) PIK3CGKDM1AMEN1KMT2ARAB9A
SCHEMBL685021 0.90 KDM1A (0.61) PIK3CGKDM1AKMT2ARAB9ANPC1
SCHEMBL6751419 0.90 KDM1A (0.81) PIK3CGKDM1AMEN1KMT2ARAB9A
SCHEMBL6751416 0.90 KDM1A (0.81) PIK3CGKDM1AMEN1KMT2ARAB9A
SCHEMBL684639 0.90 KDM1A (0.81) PIK3CGKDM1AMEN1KMT2ARAB9A
SCHEMBL684605 0.89 KDM1A (0.72) PIK3CGKDM1AMEN1KMT2ARAB9A
SCHEMBL6570129 0.88 KDM1A (0.58) KDM1AMEN1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO PIK3CG 1404/4885KDM1A 2684/4885MEN1 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.